10. Zoll Medical (ZOLL)
Company profile: Zoll, with a market value of $2 billion, makes medical equipment used to resuscitate victims of trauma or cardiac arrest.
Investor takeaway: Its shares are up 19% this year and 53% over the past three months, and have a three-year, average annual return of 88%.
Analysts give its shares four "buy" ratings, three "buy/holds," and one "hold," according to a survey of analysts by S&P.Revenue has risen steadily over the past five years and, earnings, over three years. For fiscal 2012, analysts estimate Zoll Medical will earn $1.95 per share and that will grow by 36% to $2.65 in 2013. 9. Ista Pharmaceuticals (ISTA) Company profile: Ista Pharmaceuticals, with a market value of $355 million, develops various drugs for the ophthalmic market. It is also working on allergy drugs. Investor takeaway: Ista's shares are up 21% this year, including 116% in the past three months, and have a three-year, average annual return of 69%. Analysts give the stock one "buy/hold" rating and three "holds," per S&P. For fiscal 2012, analysts estimate earnings will grow 312% to 33 cents per share. For 2011, the company reported a net loss of $57 million or $1.47 per share, but it had operating income of $2.28 per share. 8. Buffalo Wild Wings (BWLD) Company profile: Buffalo Wild Wings, with a market value of $1.6 billion, is a casual dining restaurant chain that owns and franchises 560 restaurants in 38 states. Investor takeaway: Buffalo Wild Wings' shares are up 32% this year, 42% over the past three months, and have a three-year, average annual return of 43%. Analysts give them seven "buy" ratings, one "buy/holds," nine "holds," and one "sell," according to S&P. Analysts estimate it will earn $3.28 per share this year and that that will grow by 17% to $3.85 in 2013. Revenue, earnings and cash flow are up by double-digit amounts over the past five years. 7. Mako Surgical (MAKO) Company profile: Mako Surgical, with a market value of $1.6 billion, develops a robotic device and implants for a minimally invasive knee procedure called the MAKOplasty. Investor takeaway: Its shares are up 41% over the past three months and have a three-year average annual return of 77%. Analysts give them one "buy" rating, two "buy/holds," and five "holds," according to S&P. 6. Bio-Reference Labs (BRLI) Company profile: Bio-Reference Labs, with a market value of $642 million, is a New Jersey-based company that performs chemical-diagnostic tests, including blood and urine analysis, hematology services, pap smears and other types of tests. Investor takeaway: Its shares are up 42% this year, including 65% in the past three months, and have a three-year, average annual return of 29%. Analysts give the stock three "buy" ratings and two "holds," according to a survey of analysts by S&P. Bio-Reference Labs expected to earn $1.45 per share this year, and that that will grow by 19% to $1.73 per share in 2013. The company has five years of steady revenue, earnings and cash flow growth.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV